Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide.
J Endocrinol Invest
; 41(10): 1137-1147, 2018 Oct.
Article
em En
| MEDLINE
| ID: mdl-29396758
ABSTRACT
PURPOSE:
To evaluate the effect of pasireotide on ß-cell and adipose function in patients with Cushing's disease (CD).METHODS:
Clinical and hormonal parameters, insulin secretion evaluated by HOMA-ß and by the area under the curve (AUC2h) of C-peptide during a mixed meal tolerance test and insulin sensitivity, evaluated by the euglycaemic hyperinsulinaemic clamp, were evaluated in 12 patients with active CD, before and after 6 and 12 months of pasireotide. In addition, a panel of adipokines including leptin (Ob), leptin/leptin receptor ratio (Ob/Ob-R ratio), adiponectin, resistin, visfatin, adipocyte fatty acid binding protein (AFABP) and non-esterified fatty acids (NEFAs) was evaluated at baseline and after 12 months of pasireotide.RESULTS:
During 12 months of pasireotide treatment, a significant decrease in weight (p = 0.004), BMI (p = 0.008), waist circumference (p = 0.009), urinary free cortisol (p = 0.007), fasting insulinaemia (p = 0.007), HOMA-ß (p = 0.015) and AUC2h c-peptide (p = 0.017), concomitance with an increase in fasting glycaemia (p = 0.015) and HbA1c (p = 0.030), was found. With regard to adipokines, a significant decrease in Ob (p = 0.039), Ob/Ob-R ratio (p = 0.017) and AFABP (p = 0.036) was observed concomitant with a significant increase in Ob-R (p = 0.028) after 12 months of pasireotide.CONCLUSIONS:
12 months of treatment with pasireotide in CD is associated with an impairment of insulin secretion and an improvement of adipose function without any interference in insulin sensitivity.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Somatostatina
/
Hipersecreção Hipofisária de ACTH
/
Adipocinas
/
Hormônios
/
Insulina
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article